pmid	doi	title	Hugo_Symbol
36001451	10.1097/PAS.0000000000001956	Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.	ARID1A
35879731	10.1186/s40364-022-00401-4	Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.	ARID1A
35794096	10.1038/s41467-022-31355-8	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.	ARID1A
35727053	10.1002/cncr.34348	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.	ARID1A
35454811	10.3390/cancers14081904	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.	ARID1A
35317330	10.14740/wjon1436	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	ARID1A
35172382	10.1002/JLB.5A0721-361R	Genomic heterogeneity contributed to different prognosis between adult and pediatric acute lymphoblastic.	ARID1A
35054466	10.3390/life12010073	The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.	ARID1A
35038193	10.1111/his.14617	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	ARID1A
34791836	10.1002/cam4.4422	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	ARID1A
34649275	10.1182/bloodadvances.2021005316	Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity.	ARID1A
34560683	10.1097/PAS.0000000000001813	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	ARID1A
34348985	10.1136/jclinpath-2021-207441	Clinicopathological characteristics and genetic variations of uterine tumours resembling ovarian sex cord tumours.	ARID1A
34265801	10.1097/PAS.0000000000001780	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	ARID1A
34070951	10.3390/diagnostics11060999	Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma.	ARID1A
34039950	10.1038/s41408-021-00493-5	Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.	ARID1A
33829512	10.1111/his.14378	Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.	ARID1A
33431788	10.1038/s41392-020-00437-8	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.	ARID1A
33376237	10.1038/s41392-020-00331-3	Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.	ARID1A
33252851	10.1002/ctm2.221	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	ARID1A
32978169	10.1158/0008-5472.CAN-20-2147	EZH2-Targeted Therapies in Cancer: Hype or a Reality.	ARID1A
32918521	10.1002/pbc.28704	Aggressive Langerhans cell histiocytosis following T-cell acute lymphoblastic leukemia.	ARID1A
32083995	10.1200/JCO.19.02314	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.	ARID1A
31747604	10.1016/j.celrep.2019.10.083	Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.	ARID1A
31423576	10.1111/bjh.16159	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	ARID1A
31300419	10.1182/bloodadvances.2018029546	Sporadic and endemic Burkitt lymphoma have frequent <i>FOXO1</i> mutations but distinct hotspots in the AKT recognition motif.	ARID1A
31123138	10.1136/jclinpath-2019-205727	Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis.	ARID1A
30886885	10.1016/j.gore.2019.02.007	Endometrial cancer arising after complete remission of uterine malignant lymphoma: A case report and mutation analysis.	ARID1A
30190015	10.1016/j.hoc.2018.05.007	Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.	ARID1A
30134235	10.1159/000492835	Frequent Mutations in Natural Killer/T Cell Lymphoma.	ARID1A
29989027	10.18632/oncotarget.25601	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	ARID1A
29669287	10.1016/j.celrep.2018.03.078	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.	ARID1A
29486633	10.1177/1533034618754475	Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.	ARID1A
29307627	10.1016/j.humpath.2017.12.025	Dedifferentiated liposarcoma composed predominantly of rhabdoid/epithelioid cells: a frequently misdiagnosed highly aggressive variant.	ARID1A
29222279	10.1182/asheducation-2017.1.358	Follicular lymphoma: are we ready for a risk-adapted approach?	ARID1A
29025291	10.1556/650.2017.30868	[Waldenström's macroglobulinemia and its individualized therapy options].	ARID1A
28401006		Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.	ARID1A
27872090	10.1158/0008-5472.CAN-16-1303	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.	ARID1A
27729836	10.5808/GI.2016.14.3.78	Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel.	ARID1A
27590521	10.18632/oncotarget.11773	Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.	ARID1A
27102345	10.1038/modpathol.2016.79	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.	ARID1A
26839360	10.1136/thoraxjnl-2015-207950	A patient with complex multiple genomic ALK alterations.	ARID1A
26551670	10.1038/ng.3444	Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.	ARID1A
26473533	10.1038/bcj.2015.89	Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.	ARID1A
26468873	10.1371/journal.ppat.1005158	Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma.	ARID1A
26415585	10.1038/ncomms9470	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.	ARID1A
26256760	10.1016/S1470-2045(15)00169-2	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	ARID1A
26192917	10.1038/ng.3358	Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.	ARID1A
25918285	10.1200/JCO.2014.59.2444	Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.	ARID1A
25779943	10.1158/1078-0432.CCR-14-2759	Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.	ARID1A
25444907	10.1016/j.canlet.2014.11.024	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	ARID1A
24435047	10.1182/blood-2013-05-500264	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	ARID1A
24366360	10.1182/blood-2013-09-525808	The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.	ARID1A
23292937	10.1073/pnas.1205299110	Genetic heterogeneity of diffuse large B-cell lymphoma.	ARID1A
23143597	10.1038/ng.2468	The genetic landscape of mutations in Burkitt lymphoma.	ARID1A
23091298	10.1182/blood-2012-06-437624	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.	ARID1A
22931316	10.1056/NEJMoa1200710	MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.	ARID1A
22915242	10.1007/s00428-012-1303-2	ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.	ARID1A
22585168	10.1158/2159-8290.CD-11-0208	Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.	ARID1A
21590771	10.1002/path.2911	Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.	ARID1A
19066270	10.1093/jnci/djn416	The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.	ARID1A
29486633	10.1177/1533034618754475	Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.	ARID1A
22915242	10.1007/s00428-012-1303-2	ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.	ARID1A
24435047	10.1182/blood-2013-05-500264	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	ARID1A
26446488	10.1038/ncomms9325	LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair.	ARID1A
